October 2014

Expanded Access Protocol Thymus Transplantation

Conditions:   Poor Thymic Function;   Immunodeficiency;   Athymia;   Immunoreconstitution;   Thymus Transplantation;   Low T Cell Numbers
Interventions:   Biological: Thymus Transplantation;   Procedure: Blood Draw;   Drug: Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
Sponsor:   M. Louise Markert
Available - verified December 2016

A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral

Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Other: Intravenous administration of placebo;   Drug: Intravenous administration of 1 million of MSC;   Drug: Intravenous administration of 2 million of MSC;   Drug: Intravenous administration of 4 million of MSC
Sponsors:   Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud;   Iniciativa Andaluza en Terapias Avanzadas
Recruiting - verified November 2016

European Home Mechanical Ventilation Registry

Conditions:   Pulmonary Disease, Chronic Obstructive;   Amyotrophic Lateral Sclerosis;   Spinal Cord Injury;   Muscular Dystrophies;   Obesity Hypoventilation Syndrome;   Kyphoscoliosis;   Congenital Central Hypoventilation Syndrome;   Duchenne Muscular Dystrophy;   Myopathies;   Myotonic Dystrophy
Intervention:  
Sponsors:   ResMed;   Clinical Trial Center North Hamburg Germany;   The Clinical Research Institute Munich Germany
Terminated - verified October 2016

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myelogenous Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: G-CSF;   Biological: Interleukin-2;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Rituximab;   Biological: Natural killer cell therapy;   Biological: T-cell depleted HPC transplant;   Biological: CD45RA-depleted HPC transplant